Phase I and II study of azacitidine in Japanese patients with myelodysplastic syndromes

Toshiki Uchida, Yoshiaki Ogawa, Yukio Kobayashi, Takayuki Ishikawa, Haruhiko Ohashi, Tomoko Hata, Noriko Usui, Masafumi Taniwaki, Kazunori Ohnishi, Hideki Akiyama, Keiya Ozawa, Kazuma Ohyashiki, Shinichiro Okamoto, Akihiro Tomita, Shinji Nakao, Kensei Tobinai, Michinori Ogura, Kiyoshi Ando, Tomomitsu Hotta

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

Azacitidine, an inhibitor of DNA methyltransferase, is reported to have antileukemic efficacy and is approved for the treatment of myelodysplastic syndromes in Western countries. We have conducted a Phase I/II study of azacitidine in Japanese patients with myelodysplastic syndromes to evaluate its pharmacokinetics, efficacy, and safety. In all, 53 patients received 75mg/m2 azacitidine subcutaneously or intravenously once daily for seven consecutive days on a 28-day cycle. The Cmax following intravenous administration was approximately 3.7-fold higher than that following subcutaneous administration, whereas the area under the plasma concentration-time curve from time zero to infinity was comparable for subcutaneous and intravenous administration. The bioavailability of azacitidine following subcutaneous administration was 91.1%, indicating that azacitidine is nearly completely absorbed after subcutaneous administration. The hematologic improvement and hematologic response rates were 54.9% (28/51) and 28.3% (15/53), respectively, and there were no differences between the two routes of administration. Azacitidine was generally well tolerated and clinically manageable in Japanese patients with myelodysplastic syndromes. Adverse events occurred in ≥20% of patients included hematologic toxicity, gastrointestinal events, and general disorders, such as malaise. Grade 3/4 adverse events that occurred in ≥50% of patients were all due to hematologic toxicity. The safety profile of azacitidine was generally similar for both routes of administration, with the exception of injection site reactions observed following subcutaneous administration. These results indicate that azacitidine can be expected to be a useful therapeutic agent in Japanese patients with myelodysplastic syndromes.

Original languageEnglish
Pages (from-to)1680-1686
Number of pages7
JournalCancer Science
Volume102
Issue number9
DOIs
Publication statusPublished - 2011 Sep

Fingerprint

Azacitidine
Myelodysplastic Syndromes
Intravenous Administration
Safety
Methyltransferases
Biological Availability
Pharmacokinetics
Injections
DNA
Therapeutics

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Uchida, T., Ogawa, Y., Kobayashi, Y., Ishikawa, T., Ohashi, H., Hata, T., ... Hotta, T. (2011). Phase I and II study of azacitidine in Japanese patients with myelodysplastic syndromes. Cancer Science, 102(9), 1680-1686. https://doi.org/10.1111/j.1349-7006.2011.01993.x

Phase I and II study of azacitidine in Japanese patients with myelodysplastic syndromes. / Uchida, Toshiki; Ogawa, Yoshiaki; Kobayashi, Yukio; Ishikawa, Takayuki; Ohashi, Haruhiko; Hata, Tomoko; Usui, Noriko; Taniwaki, Masafumi; Ohnishi, Kazunori; Akiyama, Hideki; Ozawa, Keiya; Ohyashiki, Kazuma; Okamoto, Shinichiro; Tomita, Akihiro; Nakao, Shinji; Tobinai, Kensei; Ogura, Michinori; Ando, Kiyoshi; Hotta, Tomomitsu.

In: Cancer Science, Vol. 102, No. 9, 09.2011, p. 1680-1686.

Research output: Contribution to journalArticle

Uchida, T, Ogawa, Y, Kobayashi, Y, Ishikawa, T, Ohashi, H, Hata, T, Usui, N, Taniwaki, M, Ohnishi, K, Akiyama, H, Ozawa, K, Ohyashiki, K, Okamoto, S, Tomita, A, Nakao, S, Tobinai, K, Ogura, M, Ando, K & Hotta, T 2011, 'Phase I and II study of azacitidine in Japanese patients with myelodysplastic syndromes', Cancer Science, vol. 102, no. 9, pp. 1680-1686. https://doi.org/10.1111/j.1349-7006.2011.01993.x
Uchida, Toshiki ; Ogawa, Yoshiaki ; Kobayashi, Yukio ; Ishikawa, Takayuki ; Ohashi, Haruhiko ; Hata, Tomoko ; Usui, Noriko ; Taniwaki, Masafumi ; Ohnishi, Kazunori ; Akiyama, Hideki ; Ozawa, Keiya ; Ohyashiki, Kazuma ; Okamoto, Shinichiro ; Tomita, Akihiro ; Nakao, Shinji ; Tobinai, Kensei ; Ogura, Michinori ; Ando, Kiyoshi ; Hotta, Tomomitsu. / Phase I and II study of azacitidine in Japanese patients with myelodysplastic syndromes. In: Cancer Science. 2011 ; Vol. 102, No. 9. pp. 1680-1686.
@article{082dfc7e5e104a7da9114a35581bf062,
title = "Phase I and II study of azacitidine in Japanese patients with myelodysplastic syndromes",
abstract = "Azacitidine, an inhibitor of DNA methyltransferase, is reported to have antileukemic efficacy and is approved for the treatment of myelodysplastic syndromes in Western countries. We have conducted a Phase I/II study of azacitidine in Japanese patients with myelodysplastic syndromes to evaluate its pharmacokinetics, efficacy, and safety. In all, 53 patients received 75mg/m2 azacitidine subcutaneously or intravenously once daily for seven consecutive days on a 28-day cycle. The Cmax following intravenous administration was approximately 3.7-fold higher than that following subcutaneous administration, whereas the area under the plasma concentration-time curve from time zero to infinity was comparable for subcutaneous and intravenous administration. The bioavailability of azacitidine following subcutaneous administration was 91.1{\%}, indicating that azacitidine is nearly completely absorbed after subcutaneous administration. The hematologic improvement and hematologic response rates were 54.9{\%} (28/51) and 28.3{\%} (15/53), respectively, and there were no differences between the two routes of administration. Azacitidine was generally well tolerated and clinically manageable in Japanese patients with myelodysplastic syndromes. Adverse events occurred in ≥20{\%} of patients included hematologic toxicity, gastrointestinal events, and general disorders, such as malaise. Grade 3/4 adverse events that occurred in ≥50{\%} of patients were all due to hematologic toxicity. The safety profile of azacitidine was generally similar for both routes of administration, with the exception of injection site reactions observed following subcutaneous administration. These results indicate that azacitidine can be expected to be a useful therapeutic agent in Japanese patients with myelodysplastic syndromes.",
author = "Toshiki Uchida and Yoshiaki Ogawa and Yukio Kobayashi and Takayuki Ishikawa and Haruhiko Ohashi and Tomoko Hata and Noriko Usui and Masafumi Taniwaki and Kazunori Ohnishi and Hideki Akiyama and Keiya Ozawa and Kazuma Ohyashiki and Shinichiro Okamoto and Akihiro Tomita and Shinji Nakao and Kensei Tobinai and Michinori Ogura and Kiyoshi Ando and Tomomitsu Hotta",
year = "2011",
month = "9",
doi = "10.1111/j.1349-7006.2011.01993.x",
language = "English",
volume = "102",
pages = "1680--1686",
journal = "Cancer Science",
issn = "1347-9032",
publisher = "Wiley-Blackwell",
number = "9",

}

TY - JOUR

T1 - Phase I and II study of azacitidine in Japanese patients with myelodysplastic syndromes

AU - Uchida, Toshiki

AU - Ogawa, Yoshiaki

AU - Kobayashi, Yukio

AU - Ishikawa, Takayuki

AU - Ohashi, Haruhiko

AU - Hata, Tomoko

AU - Usui, Noriko

AU - Taniwaki, Masafumi

AU - Ohnishi, Kazunori

AU - Akiyama, Hideki

AU - Ozawa, Keiya

AU - Ohyashiki, Kazuma

AU - Okamoto, Shinichiro

AU - Tomita, Akihiro

AU - Nakao, Shinji

AU - Tobinai, Kensei

AU - Ogura, Michinori

AU - Ando, Kiyoshi

AU - Hotta, Tomomitsu

PY - 2011/9

Y1 - 2011/9

N2 - Azacitidine, an inhibitor of DNA methyltransferase, is reported to have antileukemic efficacy and is approved for the treatment of myelodysplastic syndromes in Western countries. We have conducted a Phase I/II study of azacitidine in Japanese patients with myelodysplastic syndromes to evaluate its pharmacokinetics, efficacy, and safety. In all, 53 patients received 75mg/m2 azacitidine subcutaneously or intravenously once daily for seven consecutive days on a 28-day cycle. The Cmax following intravenous administration was approximately 3.7-fold higher than that following subcutaneous administration, whereas the area under the plasma concentration-time curve from time zero to infinity was comparable for subcutaneous and intravenous administration. The bioavailability of azacitidine following subcutaneous administration was 91.1%, indicating that azacitidine is nearly completely absorbed after subcutaneous administration. The hematologic improvement and hematologic response rates were 54.9% (28/51) and 28.3% (15/53), respectively, and there were no differences between the two routes of administration. Azacitidine was generally well tolerated and clinically manageable in Japanese patients with myelodysplastic syndromes. Adverse events occurred in ≥20% of patients included hematologic toxicity, gastrointestinal events, and general disorders, such as malaise. Grade 3/4 adverse events that occurred in ≥50% of patients were all due to hematologic toxicity. The safety profile of azacitidine was generally similar for both routes of administration, with the exception of injection site reactions observed following subcutaneous administration. These results indicate that azacitidine can be expected to be a useful therapeutic agent in Japanese patients with myelodysplastic syndromes.

AB - Azacitidine, an inhibitor of DNA methyltransferase, is reported to have antileukemic efficacy and is approved for the treatment of myelodysplastic syndromes in Western countries. We have conducted a Phase I/II study of azacitidine in Japanese patients with myelodysplastic syndromes to evaluate its pharmacokinetics, efficacy, and safety. In all, 53 patients received 75mg/m2 azacitidine subcutaneously or intravenously once daily for seven consecutive days on a 28-day cycle. The Cmax following intravenous administration was approximately 3.7-fold higher than that following subcutaneous administration, whereas the area under the plasma concentration-time curve from time zero to infinity was comparable for subcutaneous and intravenous administration. The bioavailability of azacitidine following subcutaneous administration was 91.1%, indicating that azacitidine is nearly completely absorbed after subcutaneous administration. The hematologic improvement and hematologic response rates were 54.9% (28/51) and 28.3% (15/53), respectively, and there were no differences between the two routes of administration. Azacitidine was generally well tolerated and clinically manageable in Japanese patients with myelodysplastic syndromes. Adverse events occurred in ≥20% of patients included hematologic toxicity, gastrointestinal events, and general disorders, such as malaise. Grade 3/4 adverse events that occurred in ≥50% of patients were all due to hematologic toxicity. The safety profile of azacitidine was generally similar for both routes of administration, with the exception of injection site reactions observed following subcutaneous administration. These results indicate that azacitidine can be expected to be a useful therapeutic agent in Japanese patients with myelodysplastic syndromes.

UR - http://www.scopus.com/inward/record.url?scp=80051818198&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80051818198&partnerID=8YFLogxK

U2 - 10.1111/j.1349-7006.2011.01993.x

DO - 10.1111/j.1349-7006.2011.01993.x

M3 - Article

VL - 102

SP - 1680

EP - 1686

JO - Cancer Science

JF - Cancer Science

SN - 1347-9032

IS - 9

ER -